Katharina Elisabeth Blankart : Citation Profile


Are you Katharina Elisabeth Blankart?

Universität Duisburg-Essen (95% share)
Universität Hamburg (5% share)

4

H index

0

i10 index

36

Citations

RESEARCH PRODUCTION:

17

Articles

3

Papers

RESEARCH ACTIVITY:

   11 years (2011 - 2022). See details.
   Cites by year: 3
   Journals where Katharina Elisabeth Blankart has often published
   Relations with other researchers
   Recent citing documents: 8.    Total self citations: 11 (23.4 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pfi221
   Updated: 2022-11-19    RAS profile: 2022-09-14    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Authors registered in RePEc who have co-authored more than one work in the last five years with Katharina Elisabeth Blankart.

Is cited by:

Mortimer, Duncan (2)

LEVAGGI, ROSELLA (2)

Gu, Yuanyuan (2)

Lancsar, Emily (2)

Blankart, Carl (1)

Hu, Min (1)

Fernandez, Jose Luis (1)

Leidl, Reiner (1)

Costa-Font, Joan (1)

Leidl, Reiner (1)

Iversen, Tor (1)

Cites to:

Devlin, Nancy (10)

Leidl, Reiner (8)

Leidl, Reiner (8)

Parkin, David (7)

Lichtenberg, Frank (7)

Stargardt, Tom (7)

Belotti, Federico (5)

Atella, Vincenzo (5)

Anell, Anders (5)

Depalo, Domenico (5)

Schreyögg, Jonas (4)

Main data


Where Katharina Elisabeth Blankart has published?


Journals with more than one article published# docs
Health Policy6
The European Journal of Health Economics3
IJERPH2

Recent works citing Katharina Elisabeth Blankart (2022 and 2021)


YearTitle of citing document
2021Regulatory and HTA early dialogues in medical devices. (2021). Blankart, Carl ; Penton, Hannah ; Dams, Florian ; Federici, Carlo ; Iskandar, Rowan ; Shatrov, Kosta ; Zemplenyi, Antal ; Kalo, Zoltan. In: Health Policy. RePEc:eee:hepoli:v:125:y:2021:i:10:p:1322-1329.

Full description at Econpapers || Download paper

2022How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada. (2022). Kanavos, Panos ; Mills, Mackenzie. In: Health Policy. RePEc:eee:hepoli:v:126:y:2022:i:11:p:1130-1143.

Full description at Econpapers || Download paper

2022Promoting innovation while controlling cost: The UKs approach to health technology assessment. (2022). Mossialos, Elias ; Carter, Paul ; McGuire, Alistair ; Taylor, David ; Drummond, Michael ; Anderson, Michael. In: Health Policy. RePEc:eee:hepoli:v:126:y:2022:i:3:p:224-233.

Full description at Econpapers || Download paper

2021.

Full description at Econpapers || Download paper

2022.

Full description at Econpapers || Download paper

2021Beyond price: the effects of non-financial barriers on access to drugs and health outcomes. (2021). LEVAGGI, ROSELLA ; Montefiori, Marcello ; Leporatti, Lucia. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:22:y:2021:i:4:d:10.1007_s10198-021-01270-8.

Full description at Econpapers || Download paper

2022Technology adoption by primary care physicians. (2022). Ma, Ching-to ; Iversen, Tor. In: Health Economics. RePEc:wly:hlthec:v:31:y:2022:i:3:p:443-465.

Full description at Econpapers || Download paper

2021Arzneimittelmarkt-Steuerung unter dem Einfluss von AMNOG und Festbeträgen: Forschungsprojekt im Auftrag der Bristol-Myers Squibb GmbH & Co. KGaA. (2021). Bauer, Cosima ; Giulini-Limbach, Chiara ; May, Uwe. In: IBES Diskussionsbeiträge. RePEc:zbw:udewwd:232.

Full description at Econpapers || Download paper

Works by Katharina Elisabeth Blankart:


YearTitleTypeCited
2021A Hard Look at “Soft” Cost?control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany In: CINCH Working Paper Series (since 2020).
[Full Text][Citation analysis]
paper0
.() In: .
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 0
paper
2011A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention In: Health Policy.
[Full Text][Citation analysis]
article2
2012A systematic review of coverage decision-making on health technologies—Evidence from the real world In: Health Policy.
[Full Text][Citation analysis]
article9
2013Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis In: Health Policy.
[Full Text][Citation analysis]
article5
2016Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia In: Health Policy.
[Full Text][Citation analysis]
article8
2016Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark In: Health Policy.
[Full Text][Citation analysis]
article0
2016Dispensing behaviour of pharmacies in prescription drug markets In: Health Policy.
[Full Text][Citation analysis]
article0
In: .
[Full Text][Citation analysis]
article0
In: .
[Full Text][Citation analysis]
article0
2020Are patients more adherent to newer drugs? In: Health Care Management Science.
[Full Text][Citation analysis]
article1
2022The Effects of Off-label Drug Use on Disability and Medical Expenditure In: NBER Working Papers.
[Full Text][Citation analysis]
paper0
2013Link between Process and Appraisal in Coverage Decisions In: Medical Decision Making.
[Full Text][Citation analysis]
article0
2014Early Benefit Assessment of Pharmaceuticals in Germany In: Medical Decision Making.
[Full Text][Citation analysis]
article4
2014Analysing coverage decision-making: opening Pandora’s box? In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article1
2016The diffusion of generics after patent expiry in Germany In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article1
2018The impact of physician-level drug budgets on prescribing behavior In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article3
2022Arzneimittel: Placebo bei Engpassbekämpfung In: Wirtschaftsdienst.
[Full Text][Citation analysis]
article0
2021Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe In: REGION.
[Full Text][Citation analysis]
article0
2020The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany In: Health Economics.
[Full Text][Citation analysis]
article2

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated November, 1st 2022. Contact: CitEc Team